We are pleased to share updated results from the Phase 1 trial of our CAB-EpCAM x CAB-CD3 T-cell engager (BA3182) in patients with treatment refractory metastatic adenocarcinoma, presented over the weekend at the ESMO Annual meeting. Link to Poster: https://lnkd.in/g-ZtURhj
About us
BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our Conditionally Active Biologics (CAB) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. This improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. BioAtla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
- Website
-
http://www.BioAtla.com
External link for BioAtla, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2007
- Specialties
- antibody evolution and engineering, protein evolution and engineering, development of novel cancer immunotherapies, and conditionally active biologics
Locations
-
Primary
Get directions
11085 Torreyana Rd
San Diego, California 92121, US
-
Get directions
Employees at BioAtla, Inc.
Updates
-
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA. Check out the press release on the investor section of our website here: https://lnkd.in/gXebD8iA